TY - JOUR
T1 - Ketoconazole in the treatment of chronic idiopathic central serous chorioretinopathy
AU - Meyerle, Catherine B.
AU - Freund, K. Bailey
AU - Bhatnagar, Pawan
AU - Shah, Viral
AU - Yannuzzi, Lawrence A.
PY - 2007/9/1
Y1 - 2007/9/1
N2 - PURPOSE: To determine the effect of an adrenocorticoid antagonist (ketoconazole) in the treatment of patients with central serous chorioretinopathy (CSC). METHODS: Ketoconazole was given at an oral dose of 600 mg per day for 4 weeks. Laboratory monitoring included 24-hour urinary cortisol and liver function tests at baseline, 4 weeks, and 8 weeks. Changes in greatest linear dimension were followed with fluorescein angiography at baseline, 4 weeks, and 8 weeks. Posterior pole anatomy was assessed with optical coherence tomography at baseline, 4 weeks, and 8 weeks. Ophthalmic examination and best-corrected visual acuity were assessed at each interval visit. RESULTS: Median visual acuity in the study eye remained stable at 20/40 throughout the 8-week follow-up. Median lesion height and greatest linear dimension were stable at 4 weeks and decreased at 8 weeks. CONCLUSION: Ketoconazole lowered endogenous cortisol after 4 weeks of 600 mg daily. While median visual acuity, lesion height, and greatest linear dimension remained unchanged during the month of drug treatment, there may have been a delayed therapeutic response seen at 8 weeks.
AB - PURPOSE: To determine the effect of an adrenocorticoid antagonist (ketoconazole) in the treatment of patients with central serous chorioretinopathy (CSC). METHODS: Ketoconazole was given at an oral dose of 600 mg per day for 4 weeks. Laboratory monitoring included 24-hour urinary cortisol and liver function tests at baseline, 4 weeks, and 8 weeks. Changes in greatest linear dimension were followed with fluorescein angiography at baseline, 4 weeks, and 8 weeks. Posterior pole anatomy was assessed with optical coherence tomography at baseline, 4 weeks, and 8 weeks. Ophthalmic examination and best-corrected visual acuity were assessed at each interval visit. RESULTS: Median visual acuity in the study eye remained stable at 20/40 throughout the 8-week follow-up. Median lesion height and greatest linear dimension were stable at 4 weeks and decreased at 8 weeks. CONCLUSION: Ketoconazole lowered endogenous cortisol after 4 weeks of 600 mg daily. While median visual acuity, lesion height, and greatest linear dimension remained unchanged during the month of drug treatment, there may have been a delayed therapeutic response seen at 8 weeks.
KW - Central serous chorioretinopathy
KW - Cortisol
KW - Ketoconazole
KW - Steroids
UR - http://www.scopus.com/inward/record.url?scp=34748827379&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34748827379&partnerID=8YFLogxK
U2 - 10.1097/IAE.0b013e318050ca69
DO - 10.1097/IAE.0b013e318050ca69
M3 - Article
C2 - 17891021
AN - SCOPUS:34748827379
SN - 0275-004X
VL - 27
SP - 943
EP - 946
JO - Retina
JF - Retina
IS - 7
ER -